1. Figure 4 The complement drug development pipeline
Figure 4 | The complement drug development pipeline. Complement-targeted drugs and drug candidates that are in preclinical or clinical development as of September 2017 are shown. This schematic is based on publications, conference abstracts and publicly available information on company websites. The major target is listed next to each drug name. In the preclinical section, drug candidates are ordered according to target, and their position does not reflect the stage of development. In the phase I through phase III sections, drugs are ordered according to the start date of the clinical trial; only the most advanced trial is indicated for each candidate drug. C1q, complement C1q; C1s, complement C1s; C2, complement C2; C3, complement C3; C5, complement C5; C5a, anaphylatoxin formed from the degradation of complement C5; C5aR1, C5a receptor 1; FB, factor B; FD, factor D; FH, factor H; MASP, mannose-binding lectin-associated serine protease.
Ricklin, D. et al. (2017) The renaissance of complement therapeutics
Nat. Rev. Nephrol. doi: /nrneph